RHR Pharma

RHR Pharma is a clinical-stage biopharmaceutical company dedicated to the development of treatments for central nervous system (CNS) disorders. The company was founded by Dr. Richard H. Roberts, following his successful tenure as CEO of URL Pharma, which was sold to Takeda Pharmaceuticals. RHR Pharma's primary focus is its lead candidate, RHR-102, a combination therapy designed to treat agitation in patients with Alzheimer's disease and other neuropsychiatric conditions. By optimizing known molecular pathways and drug delivery, the company seeks to provide safer and more effective therapeutic options for elderly patients suffering from cognitive and behavioral impairments. The company operates primarily out of the Research Triangle Park area in North Carolina, utilizing a lean operational model to advance its late-stage clinical assets. RHR Pharma aims to address significant unmet medical needs in the geriatric and psychiatric patient populations through specialized formulation expertise.